Sanara Medtech INC Form 4 insider transactions

MiMedx Group, Inc. announced an Agreement and Plan of Merger to acquire Sanara MedTech Inc. for a combination of cash and stock, aiming to enhance its market position.

Sanara MedTech announced a 9% revenue increase to $28.1 million for Q2 2026, alongside a pending acquisition by MiMedx.

Sanara MedTech Inc. has entered into a definitive agreement to be acquired by MiMedx Group, Inc. in a cash and stock transaction valued at approximately $350 million.

Sanara MedTech announced an agreement to combine with MiMedx Group, creating a leading regenerative medicine company focused on surgical end markets.

Sanara MedTech announced an agreement to combine with MiMedx Group, creating a leading regenerative medicine company focused on surgical markets.

MiMedx Group Inc. announced its definitive agreement to acquire Sanara MedTech Inc. for $35 per share, a move expected to significantly expand its surgical business and create a leading regenerative medicine company.

MIMEDX and Sanara MedTech announced a definitive agreement for MIMEDX to acquire Sanara, aiming to create a larger regenerative medicine company in the surgical space.

MiMedx announced an agreement to acquire Sanara MedTech, aiming to bolster its regenerative medicine offerings and expand its surgical business.

MiMedx Group, Inc. reported a 35% decrease in Q2 2026 net sales to $64 million, driven by a 61% drop in Wound sales due to Medicare reimbursement changes, while Surgical sales grew 15%. The company also announced the acquisition of Sanara MedTech for approximately $350 million.

MiMedx Group is acquiring Sanara MedTech in a cash and stock transaction valued at approximately $350 million, aiming to create a leading regenerative medicine company.

MiMedx Group, Inc. announced its definitive agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at approximately $350 million.

Director Ann Beal Salamone was granted 4,154 shares of restricted common stock by Sanara MedTech Inc. as part of the 2024 Omnibus Long-Term Incentive Plan.

Director Sara N. Ortwein was granted 4,616 shares of restricted common stock by Sanara MedTech Inc.

Director Roszell Mack III was granted 5,308 shares of restricted common stock in Sanara MedTech Inc.

Director Eric D. Tanzberger was granted 5,308 shares of restricted common stock by Sanara MedTech Inc.

Director Ronald T. Nixon was granted 4,154 shares of restricted common stock in Sanara MedTech Inc. as part of the 2024 Omnibus Long-Term Incentive Plan.

Director Robert A. DeSutter was granted 5,539 shares of restricted common stock by Sanara MedTech Inc.

Sanara MedTech Inc. director Eric D. Major was granted 4,846 shares of restricted common stock under the company's 2024 Omnibus Long-Term Incentive Plan.

Director Keith G. Myers was granted 4,385 shares of restricted stock in Sanara MedTech Inc. as part of the 2024 Omnibus Long-Term Incentive Plan.

Sanara MedTech CEO Seth D. Yon reported a transaction involving the withholding of shares for tax obligations.

Chief Operating Officer Jacob A. Waldrop reported the withholding of 378 shares to satisfy tax obligations related to restricted stock vesting.

Sanara MedTech Inc. Controller Ashley M. Mackey received a grant of 2,804 restricted common stock shares, vesting over three years.

Sanara MedTech’s COO Jacob A. Waldrop received 13,956 restricted shares under the 2024 LTIP, vesting annually from 2027 to 2029, bringing his beneficial ownership to 24,755 shares.

Sanara MedTech Inc.'s Chief Financial Officer, Elizabeth B. Taylor, was granted 12,687 shares of restricted common stock.

Sanara MedTech Inc. CEO Seth D. Yon received a grant of 25,430 restricted common shares, vesting over three years.

Sanara MedTech Inc.'s CEO, Seth D. Yon, reported a transaction involving the withholding of 491 common shares to cover tax obligations related to restricted stock vesting.

Sanara MedTech CEO Seth Yon's Form 4 filing details the withholding of 873 shares of common stock to cover tax obligations related to restricted stock vesting.

Sanara MedTech's Chief Operating Officer, Jacob A. Waldrop, reported a disposition of 714 common shares to cover tax obligations related to restricted stock vesting.

Sanara MedTech CFO Elizabeth Taylor reported a tax-related stock disposition following the vesting of restricted shares.

Sanara MedTech's Controller, Ashley M. Mackey, had 149 shares withheld to cover tax obligations from restricted stock vesting.